N/A
Completed N=42
The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Chlamydial Conjunctivitis
Source: ClinicalTrials.gov NCT01178762 ↗
Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Oct 2010
Primary outcomePrimary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants
Summary
Chlamydia trachomatis is one of the major causes of sexually transmitted disease and also the leading infectious cause of blindness in the world.Treatment of C. trachomatis eye infection has involved for a long time. The efficacy of single dose azithromycin has already been demonstrated as effective in the treatment of both trachoma and adult inclusion conjunctivitis.However, in our clinical experience, some patients of chlamydial conjunctivitis may require augmented single dose azithromycin treatments before C. trachomatis is eradicated. In this way, we would like to known the efficacy of single dose and augmented single dose azithromycin in the treatment of chlamydial conjunctivitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments |
27 | — |
Eligibility Criteria
Inclusion Criteria
- Patients of clinically chlamydial conjunctivitis suspected and proven by direct fluorescent antibody(DFA)results
Exclusion Criteria
- Patients with pregnancy or lactation, history of allergy to macrolides, evidence or history of hepatic, renal, hematological or cardiovascular disease
Data sourced from ClinicalTrials.gov (NCT01178762). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.